Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 12/20 | 0.90 |
| ▸ | ERBB2 | P04626 | 5/20 | 0.90 |
| ▸ | HPGD | P15428 | 1/20 | 0.90 |
| ▸ | HTT | P42858 | 1/20 | 0.90 |
| ▸ | BCL6 | P41182 | 2/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.47 |
| ▸ | BRAF | P15056 | 2/20 | 0.46 |
| ▸ | AXL | P30530 | 1/20 | 0.44 |
| ▸ | ERBB4 | Q15303 | 2/20 | 0.43 |
| ▸ | JAK3 | P52333 | 1/20 | 0.43 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Falnidamol SCHEMBL158563 | 0.95 | EGFR (1.00) | EGFRERBB2HPGDHTTBCL6 | |
| Falnidamol SCHEMBL29387986 | 0.95 | EGFR (1.00) | EGFRERBB2HPGDHTTBCL6 | |
| Falnidamol SCHEMBL29409569 | 0.94 | EGFR (0.98) | EGFRERBB2HPGDHTTBCL6 | |
| Falnidamol SCHEMBL29403789 | 0.94 | EGFR (0.98) | EGFRERBB2HPGDHTTBCL6 | |
| SCHEMBL6989864 | 0.93 | EGFR (0.84) | EGFRERBB2HPGDHTTBCL6 | |
| SCHEMBL8483568 | 0.90 | EGFR (0.75) | EGFRERBB2HPGDHTTBCL6 | |
| SCHEMBL8315459 | 0.90 | EGFR (0.90) | EGFRERBB2HPGDHTTBCL6 | |
| SCHEMBL7001287 | 0.89 | EGFR (0.76) | EGFRERBB2HPGDHTTBCL6 | |
| SCHEMBL6990223 | 0.88 | EGFR (0.73) | EGFRERBB2HPGDHTTBCL6 | |
| SCHEMBL6993747 | 0.88 | EGFR (0.75) | EGFRERBB2HPGDHTTBCL6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5977102-A | INHIBITORY EFFECT ON SIGNAL TRANSDUCTION MEDIATED BY TYROSINE KINASES OR EPIDERMAL GROWTH FACTOR; ANTITUMOR,-CARCINOGENIC, -METASTASIS,-PROLIFERATION AGENTS AND -INFLAMMATORY AGENTS; PSORIASIS; ANGIOGENESIS INHIBITORS; IMMUNOLOGY; | DR. KARL THOMAE GMBH (DE) | 1999-11-02 | — | — | US | disclosed |